ALIVINEKLA

COMPOSITION
Venetoclax………………………………100mg
INDICATION
• This product is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• In combination with azacitidine, or decitabine, or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
PACKAGING: 120 tablets/bottle.

Reg No: 11 L 127/24
Download ALIVINEKLA Drug Registration Certificate

Brand name: ALIVINEKLA


Composition:
Each tablet contains:
Venetoclax………………………………100mg


Indications:
• This product is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• In combination with azacitidine, or decitabine, or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.


Dosage:
• Dosing is in accordance with the directions of a physician.
• Tablets should be taken orally once daily, with a meal and water.
• Do not chew crush or break tablets.
• Perform prophylaxis for tumor lysis syndrome.


Contraindications: Concomitant use with potent CYP3A inhibitors at initiation and during ramp-up phase in patients CLL/SLL is contraindicated.


Warnings:
• Tumor lysis syndrome (TLS): expected TLS; Assess the risks for all patients.
• Neutropenia: Monitor blood count, interrupt administration, and administer at the same or reduced dose.
• Infections: Monitor for signs and symptoms of infection and treat promptly. Withhold for Grade 3 and 4 infections until resolution and resume at same or reduced dose.
• Immunization: Do not administer live attenuated vaccines prior to, during, or after treatment with Venetoclax until B-cell recovery
• Embryo fetal toxicity: may cause embryo fetal injury; It is recommended not to breastfeed during medication period.


Adverse Effects: Neutropenia, thrombocytopenia, anemia, nausea, abdominal pain, cough, oropharyngeal pain.


Dosage form: Yellow tablets.


Expiry date: 24 months from the date of manufacture.


Packaging: 120 tablets/bottle.


Storage:
• Protected from light, sealed in original packaging, and stored at 20℃- 25℃.
• Keep out of reach of children.


DISCLAIMER

The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.

For your safety:

Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.